Neurocrine Biosciences (NBIX) Tops Q4 EPS by 12c ; Offers Guidance
Tweet
Share
E-mail
Get Alerts NBIX Hot Sheet
Price: $155.85 +0.13%
Revenue Growth %: +30.8%
Financial Fact:
Research and development: 20.94M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +30.8%
Financial Fact:
Research and development: 20.94M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Neurocrine Biosciences (NASDAQ: NBIX) reported Q4 EPS of $1.69, $0.12 better than the analyst estimate of $1.57. Revenue for the quarter came in at $627.7 million versus the consensus estimate of $630.01 million.
GUIDANCE:
Neurocrine Biosciences sees FY2025 revenue of $2.5-2.6 billion, versus the consensus of $2.35 billion.
For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bessent: We Make A Market Buying Older Bonds
- OpenAI CFO: enterprise business has been on a tear
- Oracle (ORCL) call put ratio 2.3 calls to 1 put with a focus on October calls into quarter results
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
